By Dr Siva Sundararajan, General and Bariatric Surgeon, Nedlands
Obesity is a major health burden linked to chronic disease, premature death, and rising healthcare costs. In Australia, 70% of adults are overweight or obese.
Effective interventions are critical – not only to achieve meaningful weight loss but also to improve metabolic health and reduce comorbidities. For years, bariatric surgery was the only reliable option, but recently glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a powerful medical alternative.
GLP-1 agonists were a medical breakthrough. GLP-1 is an incretin hormone that boosts insulin, suppresses glucagon, slows gastric...
Obesity is a major health burden linked to chronic disease, premature death, and rising healthcare costs. In Australia, 70% of adults are overweight or obese.
Effective interventions are critical – not only to achieve meaningful weight loss but also to improve metabolic health and reduce comorbidities. For years, bariatric surgery was the only reliable option, but recently glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a powerful medical alternative.
GLP-1 agonists were a medical breakthrough. GLP-1 is an incretin hormone that boosts insulin, suppresses glucagon, slows gastric...
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.